newsfilter
← Latest News
GlobeNewswire·

DICE Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

On track to deliver topline proof-of-concept data from Phase 1 clinical trial of oral IL-17 antagonist DC-806 in healthy volunteers and psoriasis patients in mid-2022 Named development candidate DC-853 from the novel scaffold program 1 series of oral I